Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Varela, Ana
AST, NCT05926128: Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase	Recruiting	N/A	75	RoW	Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment	Fundaleu	CML	06/22	01/25
Pavlovsky, Carolina
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)	Active, not recruiting	3	650	Europe, Canada, Japan, US, RoW	Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib	Loxo Oncology, Inc., Eli Lilly and Company	Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma	06/25	01/28
AST, NCT05926128: Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase	Recruiting	N/A	75	RoW	Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment	Fundaleu	CML	06/22	01/25
Moiraghi, Beatriz
AST, NCT05926128: Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase	Recruiting	N/A	75	RoW	Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment	Fundaleu	CML	06/22	01/25
Bianchini, Michele
AST, NCT05926128: Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase	Recruiting	N/A	75	RoW	Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment	Fundaleu	CML	06/22	01/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Varela, Ana
AST, NCT05926128: Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase	Recruiting	N/A	75	RoW	Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment	Fundaleu	CML	06/22	01/25
Pavlovsky, Carolina
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)	Active, not recruiting	3	650	Europe, Canada, Japan, US, RoW	Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib	Loxo Oncology, Inc., Eli Lilly and Company	Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma	06/25	01/28
AST, NCT05926128: Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase	Recruiting	N/A	75	RoW	Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment	Fundaleu	CML	06/22	01/25
Moiraghi, Beatriz
AST, NCT05926128: Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase	Recruiting	N/A	75	RoW	Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment	Fundaleu	CML	06/22	01/25
Bianchini, Michele
AST, NCT05926128: Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase	Recruiting	N/A	75	RoW	Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment	Fundaleu	CML	06/22	01/25